Table 1 Characteristics of seven studies evaluating statins and incidence of liver cancer in people with hepatitis B or C virus infection
From: Can statins lessen the burden of virus mediated cancers?
Study | Years of study | Country | Study design | Number of centers | Age (years) | No. total population initially evaluated | No. HBV included in analysis | No. HCV included in analysis | No. male | % male | Age (mean or median) | No. statin users | % statin user | Statins evaluated | Primary outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Goh [52] | 2008–2012 | South Korea | Retrospective cohort | Single center |  ≥ 18 | 12,950 | 7713 | N/A | 5106c | 66%c | 50c | 713 | 9 | A,F,P,Pi,R,S | HCC incidence |
Hsiang [54] | 2000–2012 | China | Retrospective landmark analysis, followed by propensity weighting | Nationwide cohort |  ≥ 18 | 77,021 | 53,513 | N/A | 14,145c | 26%c | 38c | 1176 | 2 | A,F,R,S | HCC incidence |
Simon [55] | 2001–2014 | US | Retrospective cohort | Nationwide cohort | N/A | 47,549 | N/A | 9135 | 8743c | 96%c | 53 | 4165 | 46 | A,C,F,L,P,S | HCC incidence |
Simon [56]* | 2005–2013 | Sweden | Prospective propensity score-matched cohort | Nationwide cohort |  ≥ 18 | 16,668 | 3906 | 12,762 | 1992c | 51%c (HBV), 62%c (HCV) | 35c (HBV), 39c (HCV) | 1953 (HBV), 6381 (HCV) | 50 | A,P,R,S | HCC incidence |
Tsan [50] | 1997–2008 | Taiwan | Retrospective cohort | Nationwide cohort |  > 18 | 33,413 | 33,413 | N/A | 19,442 | 58% | 36 | 2785 | 8 | A,F,L,P,R,S | HCC incidence |
Tsan [57] | 1999–2010 | Taiwan | Retrospective cohort | Nationwide cohort |  > 18 | 260,864 | N/A | 260,864 | 128,263 | 49% | 50 | 35,023 | 13 | A,F,L,P,R,S | HCC incidence |
Yang [58]** | 1996–2005 | China | Retrospective cohort | Nationwide cohort | N/A | 1319 | 204 | N/A | 141 | 69% | 52 | 148 | 28 | Not specified | HCC incidence |